The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

Add Yahoo as a preferred source to see more of our stories on Google. HHS Secretary Robert F. Kennedy Jr., speaks at an event where Secretary of Agriculture Brooke Rollins signed SNAP food choice ...

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

When NPR first featured the work of Brazilian scientists and longtime best friends Patricia Neves and Ana Paula Ano Bom, they were in the early stages of an audacious attempt to break open global ...